Statera BioPharma (STU:7CB) Net Margin %: 0.00% (As of Sep. 2022)


What is Statera BioPharma Net Margin %?

Statera BioPharma STU:7CB 20 Net Margin % is 0.00% as of Sep. 2022. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Net margin is calculated as Net Income divided by its Revenue. Statera BioPharma's Net Income for the three months ended in Sep. 2022 was €-3.38 Mil. Statera BioPharma's Revenue for the three months ended in Sep. 2022 was €0.00 Mil. Therefore, Statera BioPharma's net margin for the quarter that ended in Sep. 2022 was 0.00%.

The historical rank and industry rank for Statera BioPharma's Net Margin % or its related term are showing as below:


STU:7CB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Statera BioPharma  (STU:7CB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Statera BioPharma Net Margin % Related Terms

Statera BioPharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Net Margin % Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Net Margin %
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:7CB vs NRBO, PALI, BLCM: Net Margin % Comparison

For the Biotechnology subindustry, Statera BioPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Net Margin % falls into.


Statera BioPharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Statera BioPharma's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin=Net Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-90.138/0
= %

Statera BioPharma's Net Margin for the quarter that ended in Sep. 2022 is calculated as

Net Margin=Net Income (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-3.382/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Statera BioPharma (STU:7CB) has a Net Margin % of 0.00% as of Sep. 2022. Net margin is the ratio of total net income to net sales. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Net Margin % too high?
Statera BioPharma's current Net Margin % is 0.00%. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Net Margin % compare to NRBO and PALI?
Statera BioPharma's Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current Net Margin % is 0.00% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.